CJC-1295, ipamorelin and tesamorelin compared
Three compounds can prompt growth-hormone release. The human experiments end at very different places.
The human experiments side by side
I distrust rankings assembled from such different human experiments. A prolonged blood response, a time to eating and a fat-area measurement concern different outcomes, in different people. The table preserves those differences.
| Compound | Human experiment | Result and reach |
|---|---|---|
| CJC-1295 with DAC | Small studies in healthy adults | Hormone elevation lasted days; pulses persisted over a higher baseline. Sleep, strength and lasting health benefits were not established. |
| Ipamorelin | Healthy male volunteers; adults after bowel resection | A brief hormone response was characterized; the trial of earlier tolerated eating missed its primary endpoint. |
| Tesamorelin | Adults with HIV and abdominal fat accumulation | Visceral and liver fat decreased. The approved use concerns excess abdominal fat in HIV-associated lipodystrophy. |
The healthy volunteers in the hormone experiments cannot stand in for the patients in the fat trials. Nor can results for one compound determine what happens with another. That leaves a narrower comparison than marketing often offers, but a more useful one.
Different ways to start release
CJC-1295 and tesamorelin mimic growth hormone-releasing hormone at the pituitary. Ipamorelin acts through the ghrelin receptor. The review of growth hormone-releasing hormone analogues provides context for the first route; the ipamorelin volunteer study characterizes a response through the second.
With DAC, CJC-1295 attaches to albumin and extends its stay in blood. The name no-DAC describes a short-acting form without that feature. Ipamorelin’s brief intravenous human experiment gives it a different time course. Tesamorelin has both hormone studies and trials of a particular clinical fat problem. Duration alone provides no ranking of usefulness.
CJC-1295 with ipamorelin
The distinct receptor routes explain the appeal of combining CJC-1295 with ipamorelin. I can follow that rationale without accepting the proposed outcome. The CJC-1295 duration experiment and the ipamorelin pharmacology experiment studied the compounds separately. Joining their findings on a page cannot establish the effectiveness or safety of giving them together.
Claims about better sleep, exercise recovery and a leaner appearance often arrive through community accounts. Those are anecdotal reports, not clinical evidence for the combination. Concurrent changes in training, food and other substances further complicate them. No dose or schedule follows from those accounts here.
A persuasive combination trial, to me, would have to test the combination and the benefit being claimed, with enough follow-up to investigate harm. A larger hormone response alone would leave the central question open.
Approval and later safety
CJC-1295 and ipamorelin have no approved medical indication. Tesamorelin has a prescription approval for its specified HIV-associated fat condition. That distinction changes the clinical evidence available; it does not make every proposed tesamorelin use established. All three are prohibited in sport.
The tesamorelin follow-up adds information over 52 weeks, including reaccumulation of visceral fat after treatment ended. CJC-1295’s prolonged hormone elevation and ipamorelin’s short human studies leave substantial long-term safety gaps. The rat heart-injury finding with another ghrelin-receptor agonist is a class-level concern, with no demonstrated ipamorelin injury in that experiment.
For the claimed fat benefit, the enrolled patients and the actual scans deserve priority. For tesamorelin that includes a convincing fat result in a defined population. For the broader promises around all three, the record has much further to go. The reading list retains the individual papers behind those judgments.